Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevos compuestos para la enfermedad de Alzheimer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20190513001
Publicado:
14/05/2019
Caducidad:
14/05/2020
Resumen:
Un grupo de investigación de tres universidades españolas ha desarrollado una nueva familia de ligandos del receptor imidazólico I2 con actividad antiinflamatoria y neuroprotectora, ofreciendo un nuevo enfoque terapéutico para el tratamiento de la enfermedad de Alzheimer. Los compuestos se caracterizan por presentar bastantes menos efectos secundarios cardiovasculares que otros compuestos. Los receptores imidazólicos I2 están implicados en procesos fisiológicos relacionados con la anelgesia, antiinflamación y neuroprotección, ofreciendo una amplia variedad de aplicaciones para compuestos dirigidos a este tipo de proteínas. El grupo de investigación busca una compañía farmacéutica interesada en desarrollar un fármaco para el alzhéimer y establecer un acuerdo de licencia.

Details

Tittle:
New compounds targeting Alzheimer´s disease offered for licensing
Summary:
A research team composed by researchers from three Spanish Universities has developed a new family of I2 Imidazoline Receptor ligands with anti-inflammatory and neuroprotective activity, opening a new therapeutic approach for Alzheimer´s disease treatment. The compounds are characterized by presenting considerably less cardiovascular side-effects compared to existing ones. A pharmaceutical company interested in developing an Alzheimer´s disease drug is being sought for a licensing agreement.
Description:
Alzheimer´s disease is the largest unmet medical need in neurology. Existing drugs have scarce or limited efficacy and no new cognitive enhancer drugs are available currently.
A new family of I2 Imidazoline Receptor ligands (compounds referred to as I2-IR ligands), selective against I2-IR and with potential less side-effects, has been developed by a research team composed by researchers from three Spanish Universities. The team has specialists in the area of synthesis of heterocyclic compounds with interest in the treatment of Alzheimer´s disease, neuropharmacology and neuropsychopharmacology.
The new family of synthetic compounds developed relates to the field of compounds with high affinity for imidazoline receptors of the I2-type, which have been associated with prevention or treatment of human brain disorders, such as depression and Alzheimer´s disease, pain modulation, and inflammation.
I2-IR are involved in physiologic processes related to analgesia, anti-inflammation and neuroprotection among others, which offers a wide range of applications for compounds targeting this type of proteins.
It is also known that in Alzheimer´s disease brain patients the density (Bmax) of I2 imidazoline binding sites is significantly higher than in control samples, and that I2-IR ligands have neuroprotectant properties. In this regard, other I2-IR ligands have been developed and tested, but most of them show cardiac side-effects due to their activity upon a2-adrenergic receptors (a2-AR).
Inspired in this rational, researchers focused their effort on developing compounds targeting selectively I2-IR; avoiding side-effects due to a2-AR activation and opening a new therapeutic approach for Alzheimer´s disease treatment.
However, given the nature of I2-IR, other indications may also be targeted, such as osteoarthritis pain.
Advantages and Innovations:
- Potentially less cardiovascular side-effects.
- A new therapeutic approach for Alzheimer´s disease treatment with anti-inflammatory and neuroprotective activity.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
European Patent application filed on December 21st, 2017.

Partner sought

Type and Role of Partner Sought:
The research team seeks pharmaceutical companies in all countries engaged in the development of Alzheimer´s disease drugs and interested in a license agreement. The company should be able to continue the development of the invention as well as to perform dose-response, toxicity and side effects studies.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001014 Neurología, investigación cerebral
06001015 Productos farmacéuticos / medicamentos